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Drug-eluting microspheresAbstract Purpose: To investigate the efﬁcacy of transarterial chemoembolization (TACE) with
microspheres (HepaSphere) loaded with doxorubicin in patients with hepatocellular carcinoma
(HCC).
Materials and methods: From April to December 2013, 50 patients with HCC were treated by selec-
tive TACE using HepaSphere microspheres loaded with doxorubicin. The size of the lesions was
from 2 to 9 cm (mean 5.2).
Results: All of the procedures were technically successful, and there were no major complications.
At 1-month follow-up, there was complete tumor response in 48%, partial response in 42%, stable
disease in 10%, and there were no cases of disease progression. At 3-month follow-up, complete
tumor response was observed in 42%, partial response in 38%, stable disease in 16%, and progres-
sive disease in 4%. At 6-month follow-up, there was complete response in 40%, partial response in
36%, stable disease in 10% and progressive disease in 14%.Within the initial 6-month follow-up,
TACE with HepaSphere was successfully repeated once in 3 patients, whereas 2 patients underwent
the procedure twice.
Conclusion: Chemoembolization using doxorubicin-loaded HepaSphere is a safe and effective
treatment of HCC as demonstrated by the low complication rate, and increased tumor response.
When complete tumor response is not achieved, additional treatments can be performed without
difﬁculties.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Hepatocellular carcinoma (HCC) represents the ﬁfth most
common cancer in the world and ranks third among cancer-
related deaths, and its annual incidence continues to increase.
HCC patients almost invariably suffer from a concomitant
chronic liver disease that is mainly caused by viral hepatitis.
The choice of treatment for HCC should take into account sev-
eral prognostic factors, including number and size of tumor
nodules, portal invasion, presence or absence of cirrhosis, and
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with early-stage HCC are candidates for potentially curative
treatments, such as surgical resection, liver transplantation,
and percutaneous ablation techniques (2,3), all of which are
capable of eradicating the tumor and prolonging survival. Cur-
rently, the 5-year survival rate in patients with early-stage HCC
treated with radical intent is approximately 70%; however,
when the disease has reached the intermediate or advanced
stage, the 3-year survival rate decreases to 10–50% (4). How-
ever, 80% of patients are diagnosed at an intermediate stage
of disease (1,4). In these patients, transarterial chemoemboliza-
tion (TACE) is recommended as ﬁrst-line non-curative treat-
ment (5–8) because it is able to improve survival compared
with conservative therapy and transarterial embolization.
Recent randomized trials have shown statistical survival
beneﬁts of TACE in patients with unresectable HCC over sup-
portive care or systemic chemotherapy (7,9). The function of
TACE is twofold and includes de-arterialization of the tumor
and selective delivery of chemotherapeutic agents to the tumor.
De-arterialization of HCC is achieved by the selective arterial
injection of iodized oil and embolic particles and causes ische-
mic damage, as HCC is arterial dependent. In addition, the
iodized oil also induces a temporary obstruction of portal ven-
ules through the peribiliary plexus (10). The role of ischemia
has been documented in studies in which even bland emboliza-
tion was effective for HCC (11,12). In addition, pharmacoki-
netic studies have shown that TACE with iodized oil lowers
the peak concentrations of chemotherapeutics in the systemic
circulation and increases the intratumoral concentration and
half-life of doxorubicin in the tumor (13). A number of studies
have also addressed the role of lipiodol in TACE and showed
increased deposition of lipiodol and adriamycin in the tumor
compared to the adjacent non-tumorous liver (14,15).
Transarterial chemoembolization with doxorubicin drug-
eluting beads (DEBs) is a well-known locoregional treatment
for HCC that has been evaluated by multiple randomized con-
trolled studies. More recent DEB transarterial chemoemboli-
zation studies have shown fewer side effects and less toxicity
compared with conventional transarterial chemoembolization
and are at least as effective as conventional transarterial
chemoembolization (16–18).
Recently two types of drug-loaded carriers have been intro-
duced: DC Beads (Biocompatible UK Limited, Surrey, UK)
and HepaSphere microspheres (Biosphere Medical, France).
They are represented by non-absorbable microspheres loaded
with the anticancer drug, which can be released in a controlled
and prolonged manner into the tumor with lower systemic
toxic exposure (19).
HepaSphere microspheres are expandable biocompatible
microspheres made of sodium acrylate/vinyl alcohol copoly-
mer. The product is approved and indicated in Europe for
hepatic embolisation and chemoembolization. First developed
in Japan by Hori and produced by Biosphere Medical
(France), the microspheres are sold in dehydrated form. When
placed in contact with physiologic saline solution or nonionic
(isotonic) contrast medium, they increase in volume in a
controlled manner. The ﬁnal size of the swollen particle is pre-
dictable and ranges from 200 to 400 lm (for 50- to 100-lm ‘‘dry-
state’’ spheres) to 600 to 800 lm (for 150- to 200-lm ‘‘dry-state’’
spheres). Therefore, even the smallest HepaSphere micro-
sphere is larger than the smallest size DC Bead (100–300 lm).
The polymer contained within the HepaSphere is anionicand carries a negative electrical charge. This anionic property
captures molecules with an opposite electrical charge, such as
doxorubicin or epirubicin; this property, together with a reser-
voir effect, enables large quantities of chemotherapeutic agents
to be carried within the microsphere; the estimated loading
capacity is 50 mg/vial of beads. When used during a TACE
procedure, the associated beneﬁt of sequestering the chemo-
therapeutic agent within the sphere is limited systemic expo-
sure of drug, thus minimizing chemotherapeutic systemic
effects and toxicity. The low systemic levels of doxorubicin
were also shown in the ﬁrst published human study of Varela
et al. that showed that there was a 2-log reduction in plasma
doxorubicin-loaded beads compared with conventional trans-
catheter arterial chemoembolization (TACE) (22).
The use of a permanent embolic agent implies the need for
superselective catheterization to spare the nontumoral paren-
chyma. For this reason, TACE with microspheres should not
be performed in patients with multiple and diffuse tumor nod-
ules or with nodules supplied by cystic or phrenic arteries.
Moreover, it is essential to avoid distant liver embolization by
small-size particles, which might block collateral supply and
cause severe necrosis of the non-tumoral parenchyma. Extrahe-
patic embolization has also been advocated as having a possible
collateral effect, particularly when using small particles.
Patients received chemoembolization with doxorubicin
loaded beads at doses adjusted for bilirubin and body surface
area (range: 47–150 mg). Doxorubicin Cmax (peak drug con-
centration) and AUC (area under the curve) were signiﬁcantly
lower in patients treated with TACE with microspheres than in
conventional TACE patients (p= 0.00002 and p= 0.001,
respectively) (20) .
The aim of this study was to present the 1-, 3- and 6-months
clinical results of unresectable HCC using HepaSphere micro-
spheres loaded with a chemotherapeutic agent (doxorubicin).
The primary efﬁcacy endpoint was the 6-month tumor
response rate, according to the amended EASL response crite-
ria, an accepted method for assessing tumor necrosis following
locoregional therapy (25).
2. Patients and methods
2.1. Patients
Our study extended between April and December 2013, includ-
ing 50 patients (36 male and 14 females), mean age 58 years
(range 52–64 years) with lesions 2–9 cm (mean 5.2) were trea-
ted by selective TACE using Hepasphere microspheres. All
patients had cirrhosis-related HCC that was developed on an
underlying controlled hepatitis infection. (HBV, n= 11;
HCV, n= 29; HB and C, n= 10). 35 of 50 (70%) patients
had elevated alpha-fetoprotein (AFP) (mean 617 ± 1409
ng/ml; range 21.3–3810 L). Diagnosis of HCC was conﬁrmed
either by biopsy (n= 17), or by a combination of elevated
alpha-fetoprotein (AFP)––above 400 ng/ml––and a new lesion
(>2 cm) at CT (n= 33).
2.2. Inclusion criteria
Patients with HCC unsuitable for resection or percutaneous
ablation, patients with potentially resectable lesions but of
high risk for surgery were also enrolled. Also included were
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(in terms of tumor size) but considered high risk due to loca-
tion (close to gall bladder, liver hilum, liver capsule, dia-
phragm, or pericardium). Patients with compensated
cirrhosis––Child A or B––were included in this study (Child–
Pugh score was A in 28 and B in 22); bilirubin <3 mg/dL,
albumin >2.5 g/dL, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT) <270 IU/L, and a good perfor-
mance status an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1.
2.3. Exclusion criteria
Patients with creatinine >2 mg/dL, portosystemic shunts, hep-
atofugal blood ﬂow, thrombus within the main portal vein,
extrahepatic metastases, advanced hepatic diseases (bilirubin
levels >3 mg/dL, AST or ALT >5 · upper limit of normal
or >250 U/l), advanced tumoral disease (vascular invasion
or extrahepatic spread, or diffuse HCC, deﬁned as >50% liver
involvement), or contraindications for doxorubicin adminis-
tration or another extra-hepatic primary tumor.
3. Procedure
The preparation of HepaSphere is relatively simple and con-
sists of placing the chemotherapeutic (doxorubicin) solution
(50 mg/vial) mixed with 5 ml physiologic saline or non-ionic
contrast medium (300 mg/ml optiray) then injecting the mix-
ture directly into the vacuum-sealed vial of HepaSphere. It is
necessary to wait at least 20 min to be certain that >90% of
the chemotherapeutic solution has been absorbed by the
microspheres. Then the drug-loaded microspheres are aspi-
rated from the vial, and additional contrast medium or saline
is added to obtain a ﬁnal injectable volume of 20 cc.
Prior to embolization, angiography of the hepatic and mes-
enteric artery was performed to map liver vascular anatomy,
check for arteriovenous shunts, and identify arterial feeders
of the tumor. Sometimes angiography for the phrenic and
intercostals arteries may be needed (in 2 patients of 50). The
arterial branches feeding the tumor were selectively catheter-
ized by a microcatheter to proceed with TACE and to ensure
better preservation of the surrounding non-tumoral liver tis-
sue. The injection of the spheres was performed far from the
origin of the gastroduodenal, right gastric, and cystic arteries.
TACE was performed by way of a slow injection of the mix-
ture of the HepaSphere microspheres loaded with chemother-
apeutic agent and the nonionic isotonic contrast medium,
which improves the radiopacity of the mixture, to perform a
controlled injection under ﬂuoroscopic guidance. Any reﬂux
that may have occurred and revealed contrastographic impreg-
nation within and around the target lesions, up to the complete
embolisation of the arteries feeding the lesions, was avoided.
Patients received intravenous analgesic and antiemetic medica-
tions before and/or during the procedure and post-procedure
oral antibiotic, antiemetic and analgesic.
Tumor response to treatment was assessed by imaging and
AFP values. At imaging tumor response was measured accord-
ing to the criteria adopted by the European Association for the
Study of the Liver Disease (EASL) notably measuring the lon-
gest diameter of the viable tumor against the longest total
tumor diameter. The percentage of tumor necrosis was alsorecorded. The necrotic area was identiﬁed when a low den-
sity/low-echogenicity/ﬂuid signal area that was non-enhancing
in any of the time phases was seen. The EASL has ofﬁcially rec-
ommended the use of contrast enhanced CT in the evaluation
of response to treatment, and acknowledged as ‘‘viable areas’’
those that ‘‘present enhancement’’ and ‘‘necrotic’’ those that
‘‘do not present enhancement’’ (1). The EASL response criteria
were preferred since they take into account the development of
necrosis and not only the size of the treated lesion as in the
RECIST (Response Evaluation Criteria In Solid Tumor) crite-
ria (which depend only in shrinkage in size) since it is acknowl-
edged that it is common for liver tumors to liquefy without a
signiﬁcant change in total lesion diameter within short fol-
low-up periods (21). In the EASL criteria complete response
(CR) is recorded when complete disappearance of all known
disease and no new lesions are seen; Partial response (PR) when
a 50% reduction in viable tumoral area of all measurable
lesions is present; stable disease (SD) in all other cases and pro-
gressive disease (PD) when there is a 25% increase in size of one
or more measurable lesions or if new lesions appear (1).
In imaging, multislice computed tomography (MSCT)
using a multiphase protocol is used, including a nonenhanced
acquisition followed by intravenous injection of iodized con-
trast media (120 ml) at a ﬂow rate of 3 ml/s. Arterial (delay
30 s), venous (delay 80 s) and delayed (delay 180 s) scans were
obtained with 5-mm slice thickness and 2.5-mm reconstruction
intervals. Follow-up was conducted at 1, 3 and again at
6 months after treatment.
MSCT images were reviewed by two expert radiologists by
consensus. When the residual viable tumor was at least 1 cm in
maximum axial diameter, further treatments were scheduled
(TACE ‘‘on demand’’). Patients undergoing different treat-
ment modalities (percutaneous ethanol injection, radiofre-
quency ablation, orthotopic liver transplantation, surgical
resection, and conventional TACE) were censored at the time
of the repeat procedure.
4. Results
4.1. Patients characteristics
Table 1 represents the baseline for the patients and disease
characteristics who underwent TACE with drug eluting micro-
spheres (n:50).
4.2. Procedural
Procedural technical success, which was deﬁned by complete
devascularization of all target lesions at the end of the proce-
dure, was 100%.
4.3. Mortality
The 30-day mortality rate was 0%, whereas the overall mortal-
ity rate at 6 months was 2% (1 of 50 patients); 1 patient death
was caused by hepatic failure at 6 months after TACE.
4.4. Complications
No periprocedural major complications were observed. The
mean hospital stay after each embolization was 1–2 days. Post
Table 2 Tumor response according to
EASL criteria.
Response n (%)
One month follow up
Complete 24 (48)
Partial response 21 (42)
Stable disease 5 (10)
Progressive disease 0 (0)
Three months follow up
Complete 21 (42)
Partial response 19 (38)
Stable disease 8 (16)
Progressive disease 2 (4)
Six months follow up
Complete response 20 (40)
Partial response 18 (36)
Stable disease 5 (10)
Progressive disease 7 (14)
Table 1 Baseline characteristics for the patients.
Characteristics Value
Sex – n (%)
Male 36 (72)
Female 14 (28)
Age, mean ± SD (range) years 58 ± 6.53 (52–64)
Mean lesion diameter, cm (range) 5.6 (3–9)
Child–Pugh status – n (%)
A 28 (56)
B 22 (44)
Total bilirubin – median (range)
(mg/dL)
1.1 (0.5–2)
ECOG performance status – n (%)
0 27 (54)
1 23 (46)
Hepatitis – n (%)
B 11 (22)
C 29 (58)
B & C 10 (20)
Albumin – median (range) (g/dL) 3.3 (2.5–4.2)
AFP – mean ± SD (range) (ng/ml) 702 ± 1200 (21.3–3120)
0–100 n (%) 15 (30)
100–400 n (%) 8 (16)
>400 n (%) 27 (54)
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ing) of various severity developed in most of the patients (45
of 50 patients, 90%) and lasted for 1–5 days and was treated
with classical oral antipyretic and antiemetic drugs One patient
(2%) had mild self limited right sided pleural effusion. One
patient (2%), was complicated by liver abscess, which necessi-
tated hospitalization for ﬁve days and responded well to paren-
tral antibiotics. The overall complication rates excluding PES
were 4%.
4.5. Laboratory
Laboratory tests carried out periprocedurally showed; serum
bilirubin, aspartate aminotransferase and ALT levels showed
an increase in 1–3 days after embolization in 20 patients
(40%) and returned to near pre-embolization values at two
weeks post procedure. Albumin levels remained relatively con-
stant, with no statistically signiﬁcant changes compared to the
baseline. No evident variations were seen in blood parameters
regarding renal function. The AFP follow up revealed a
signiﬁcant reduction (p= 0.007) in 33 patients from the 35
patients who had elevated preprocedure AFP (mean 31.7 ±
15.72 ng/ml; range 7.3–55).
4.6. Tumor response
The tumor response rate was assessed at 1-, 3- and 6-months
(Fig. 5, Table 2), according to the amended EASL response
criteria, an accepted method for assessing tumor necrosis fol-
lowing locoregional therapy (1).
One month after treatment (baseline), MSCT showed com-
plete tumor response in 24 of 50 (48%) (Fig. 1E and F), partial
response in 21 of 50 (42%), and stable disease in 5 of 50 (10%)
patients, and there were no cases of disease progression.At 3-months after treatment, complete tumor response was
observed in 21 of 50 (42%), partial response in 19 of 50 (38%),
stable disease in 8 of 50 (16%) patients, and progressive disease
in 2 of 50 (4%) (see Fig. 2).
Six-months after treatment MSCT at 6 months showed a
complete response in 20 of 50 (40%), partial response in 18
of 50 (36%), stable disease in of 5 of 50 (10%) and progressive
disease in 7 of 50 (14%) (Table 2).
Within the initial 6-month follow-up, TACE with Hepa-
Sphere was successfully repeated once in 3 patients, whereas
2 patients underwent the procedure twice (see Fig. 3).
5. Discussion
In the absence of vascular invasion and extrahepatic tumor
spread, TACE represents the ﬁrst-line approach in patients
with HCC that is not suitable for curative treatment (8) In
the attempt to increase local efﬁcacy and reduce the side effects
of the procedure, several vendors have developed micro-
spheres, either to be used for bland embolization or to be
loaded with chemotherapeutic agents.(23).
The results of our clinical trial demonstrated the feasibility
and safety of TACE with HepaSphere; the technical success
rate was 100%, and there were no major complications. The
procedure was well tolerated by the majority of the patients;
except for postembolization syndrome which was noted in
most of patients with variable degrees, the overall complica-
tion rates were 4%. Moreover, no evident increase in liver
enzyme levels was observed periprocedurally. Thus, low sys-
temic drug toxicity can be supposed, as already demonstrated
with DC Beads.
The tumor response was evaluated according to the WHO
criteria as modiﬁed according to the EASL recommendations
(1), which take into account only residual viable tumor tissue
as represented by persistent intra-tumoral arterial contrast
uptake. At 1 month follow-up, we observed a high objective
response rate (90%), which is comparable with the reported
results obtained with DC-Beads (17,22). In our series, TACE
was repeated only ‘‘on demand’’, in the presence of residual
viable tumor at least 1 cm in diameter; during follow-up 5
Fig. 1 Male patient 55 years old. (A) and (B) Triphasic spiral CT scan arterial phase showing a well-deﬁned +5 cm enhancing lesion in
the right hepatic lobe segment VI adherent to the colon. (C) Selective hepatic artery angiogram showing vascular blush at segment VI and
(D) After chemoembolization with drug eluting Hepaspheres showing disappearance of tumor blush. (E, F) Same CT cuts after
chemoembolization showing well-deﬁned hypodense area with no contrast enhancement.
Efﬁcacy of TACE with microspheres in hepatocellular carcinoma chemoembolization for hepatocellular 765patients repeated treatments 1 or 2 times. On the contrary,
other trials have been based on multiple embolizations rou-
tinely repeated every 2–3 months. In our opinion, this
approach may not represent the right treatment schedule for
all patients (see Fig. 4).
In this study the TACE with microspheres was efﬁcacious
as measured by tumor response and necrosis and the statisti-
cally signiﬁcant decrease in tumor size, percentage necrosis,
and AFP levels following successive embolizations. At6 months follow up, the rate of objective response according
to EASL criteria was 76%, complete response was observed
in 40%, partial response at 36%, stable disease at 10% and
disease progression at 14%. Grosso et al. (23) at 6 months fol-
low up observed similar high objective (76.7%), yet complete
response was noted at 51.6%, partial response at 25.8%, and
progressive disease at 22.6% Similarly, high percentages of
objective response were observed in the study by Varela
et al., who reported a response rate of 75% in their series of
Fig. 2 Male patient 59 years old. (A) and (B) Triphasic spiral CT scan arterial phase showing multiple bilobar scattered enhancing focal
lesions (largest ±3 cm). (C) Selective hepatic artery angiogram showing multiple bilobar scattered vascular blushes of the lesions. (D)
After chemoembolization with drug eluting Hepaspheres with disappearance of tumor blushes. (E, F) Same CT cuts after
chemoembolization showing the lesions being hypodense with no contrast enhancement and no residual viable tumor tissue.
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cin-loaded beads (19). A valid comparison with previously
reported data is difﬁcult due to the inhomogeneity in patient
selection, chemotherapeutic agents, and reporting criteria(24). However, it is clear that until now published results on
conventional TACE substantiate lower rates of response, with
a mean complete response rate of 6% and a mean partial
response rate of 26.9% (range, 15–55%) (7,9,25,26). Pelletier
Fig. 3 Male patient 62 years old. (A) and (B) Triphasic spiral CT scan arterial phase showing a wedge shaped ill-deﬁned right hepatic
lobe segment VI subcapsular lesion. (C) Selective hepatic artery angiogram showing vascular blush at segment VI. (D) After
chemoembolization with drug eluting Hepaspheres showing disappearance of the vascular blush. (E, F) Same CT cuts after
chemoembolization, where the lesion was shown to be hypodense and non-enhancing denoting necrosis.
Efﬁcacy of TACE with microspheres in hepatocellular carcinoma chemoembolization for hepatocellular 767et al. (26) reported a complete response in 4 of their 42 patients
(9.52%) and a partial response in 3 (7.14%) HCC patients
treated with TACE. Llovet et al. (6) observed an objectiveresponse sustained for at least 6 months in 35% of the TACE
group. Lin et al. reported a complete response in 1 of his 63
patients (1.58%) and a partial response in 61.9% after multiple
Fig. 4 Male patient 53 years old. (A) and (B) Triphasic spiral CT scan arterial phase showing a well-deﬁned right hepatic lobe
subcapsular enhancing expophytic lesion. (C) Selective hepatic artery angiogram showing vascular blush at segment IV. (D) After
chemoembolization with drug eluting Hepaspheres showing disappearance of the vascular blush. (E, F) Same CT cuts after
chemoembolization showing the lesion to be completely hypodense and non-enhancing denoting complete necrosis of the tumor.
768 W.M. Hetta, N. ShebriaTACE sessions and 47.6% after a single TACE session
followed by systemic chemotherapy (27).
In conclusion, our results suggest that TACE with
HepaSphere is a safe and effective treatment of HCC asdemonstrated by the low complication rate, and increased
tumor response. When complete tumor response is not
achieved, additional treatments can be performed without
difﬁculties. Further studies with larger series and
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Fig. 5 Tumor response according to EASL criteria at one, three
and six months follow up.
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minary results.
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